KYTX240816P7500
- 0.20
- -0.30-60.00%
Kyverna Therapeutics Newsroom
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Leerink Partners Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $48
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
Express News | HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
Kyverna (KYTX) Sees Pre-Market Surge After Regulatory Milestone
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
Kyverna Therapeutics' KYV-101 Gains FDA Advanced Therapy Designation
Express News | Kyverna Therapeutics Shares Are Trading Higher After the Company Announced It Received FDA Regenerative Medicine Advanced Therapy Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-person Syndrome
Express News | Kyverna's Kyv-101 Receives U.S. FDA Rmat Designation for Kyv-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
H.C. Wainwright Starts Kyverna at Neutral, Says Awaiting More Data
Kyverna Therapeutics Initiated at Neutral by HC Wainwright & Co.
Kyverna Therapeutics Analyst Ratings
Express News | Kyverna Therapeutics, Inc : H.c. Wainwright Initiates Coverage With Neutral Rating and Target Price $8
Sector Update: Health Care Stocks Higher Late Afternoon
Kyverna Gains as FDA Clears Trial for Lead Therapy
Kyverna Therapeutics Gets FDA IND Clearance for KYV-101
Express News | Kyverna Therapeutics Shares Are Trading Higher After the Company Announced KYV-101 Received FDA IND Clearance for the Treatment of Patients With Treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Express News | Kyverna's Kyv-101 Receives U.S. FDA Ind Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the Kysa-8 Phase 2 Trial
Sector Update: Health Care Stocks Decrease Late Afternoon
Sector Update: Health Care